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Post-modern society and psychopathology 
The past two decades have been marked by dramatic social changes, widely characterized 
by the term “postmodern”. These major transformations have had profound and complex 
implications for psychiatry, influencing mental health risk factors, dynamics in clinical 
encounters, styles of help-seeking behavior and clinical outcomes. Underlying themes of 
postmodern thought that are particularly relevant to psychiatry include: individualization 
and social roles; the nature of self-identity and intimacy; future orientation (Whitley r. 2008) 
1. 
A defining element of post-modernity, also driven by the massive spread of signification 
through the Internet, is an absolute reliance on the present to the exclusion or proportional 
reduction of the past and future. As first described by Edmund Husserl2 and Bin Kimura3 
with the notion of the presentatio or intrafaestum modality, the present is disconnected from 
preoccupations with the future and the past (including feelings of guilt). Contemporary 
adolescents and young adults are restricted to instantaneity, with loss of the ability to wait. 
The sociologist Oriel Sullivan’s notion of ‘speed-up society’ echoes this general 
acceleration of temporal patterns4 (i.e., increase in “time intensity”, feelings of “time 
pressure”). For instance, Rosa5 (2013) describes: acting at a faster rhythm throughout the 
day; getting rid of pauses or intervals between our actions; increased multitasking. In 
theoretical analyses of post-modern social acceleration and popularizations of the idea of the 
‘speed-up society’ 6,7,8(e.g. Colvile, 2016; Crary, 2013; Schulte, 2014), the increasing 
tempo of daily life is considered central to social change. Many recent accounts of temporal 
acceleration are directly related to the effect of Technology (Information and 
Communication Technology- ICT). There have been huge changes in ICT over the past 
decade, and this is reflected in a growing acceleration of interconnectivity, digitalization and 
gaming technologies, with major effects on perceptions of time pressure.  
The paradigm of liquid society, first introduced by Zygmunt Bauman9, underscores constant 
change, discontinuity and lack of structure in modern social life; doubt and perplexity are 
the only stable elements. A flame is an effective metaphorical image of this condition: an 
open system that constantly works to maintain an equilibrium, never evolving in an 
organized temporal structure. Meares10 argues that the existential situation of these subjects 
is dominated by point-events that never meet. Existence is “held hostage” by an eternal 
present, absorbed into immediacy, resulting in feelings of unreality and sometimes 
heightened excitement, anger, impulsivity. In post-modern adolescents/young adults, these 
emotional states are accompanied by dysphoric mood. In this context, psychoactive 
substances act as powerful catalysts, enhancing this a-temporal rewarding experience. 
 
 
Substance Use Disorders: the new scenario 
 
Licit and illicit psychoactive substances are cheap and easily-available to the post-modern 
adolescent, allowing for rapid and effortless adjustments of consciousness and emotional 
states to the ever-changing present. Substance use disorders (SUDs) are a major health 
concern: in 2010 SUDs were among the leading causes of years lived with disability 
worldwide [Whiteford, L. Degenhardt, 2015] 11. Currently substance use is so widespread 
that it can be hardly defined as an aberrant behavior, although consequences are dramatic in 
terms of mortality and psychiatric load. As discussed by Devereux12, every society has its 
own norms and rules, providing the individual with different possible ways of conveying 
both illness/distress and success/fulfillment. In post-modern society, substance use is 
connected to both scenarios. Stimulants are often thought to support successful lifestyles, 
“empowering” and enhancing the narcissistic invulnerability that permeates certain 
personality structures. On the other hand, substance use typically has the effect of producing 
an experience of wholeness, that excludes complexity and heterogeneity in favor of the 
security of a single experience, thus dampening psychological distress and offsetting 
feelings of inadequacy and fragmentation of the self in vulnerable subjects who have 
difficulty coping with “speed-up”. In this view, SUDs and associated psychopathology are a 
sort of culture-bound syndrome, profoundly rooted in the fundamentals of liquid post-
modernity.  
In addition to ‘traditional’ psychoactive substances, novel psychoactive substances (NPS) 
are raising increasing international concern, especially in relation to the fast-moving and 
potentially limitless nature of their online market (Cinosi et al., 2015; Schifano, Leoni, 
Martinotti, Rawaf & Rovetto, 2003; Schifano et al., 2005; Santacroce, Corazza, Martinotti, 
Bersani, Valeriani & Di Giannantonio, 2015; Martinotti et al., 2015a; Corazza et al., 2014) 
13,14,15,16,17,18. NPS have been legally defined by the European Union (EU) as new narcotic 
or psychotropic drugs, in pure form or preparation, that are not scheduled under the Single 
Convention on Narcotic Drugs of 1961 or the Convention on Psychotropic Substances of 
1971, but pose a public health threat potentially comparable to substances listed in those 
conventions (Council of the EU decision 2005/387/JHA) [United Nations Office on Drugs 
and Crime (UNODC), World Drug Report, United Nations Publication, Sales]) 19. In 2017, 
the total number of NPS in the EU was over 670, of which 632 were notified after 2004 
(EMCDDA, 2018). NPS are often unknown to health professionals, mainly due to lack of 
evidence-based sources of information (O. Corazza, S. Assi et al., 2013) 20. Internet (i.e., 
online forums, chat rooms, blogs) has emerged as a primary source of information on drugs 
in general and NPS in particular. An estimated 61% of young Europeans aged 15-24 years 
typically quote the Internet as a source of information on drugs [Eurobarometer, Young 
people and drugs: analytical report, 2009, http://ec.europa.eu/public opinion/flash/fl 233 
en.pdf] 21. Users share their experiences with different substances, and recommend sources 
and routes of delivery. Vulnerable young consumers are targeted by aggressive marketing 
strategies (i.e., attractive names, colorful packaging, free samples to test), increasing the 
likelihood of early exposure to substances. NPS are mostly unregulated, and this may 
increase their popularity as well as the flawed perception of low risks associated with use. 
Unfortunately, to date, few surveys on NPS diffusion have been conducted. Furthermore, 
there is increasing evidence that NPS use is often unintentional (Salomone, Palamar, et al 
2017) 22. Growing evidence supports the potential serious psychiatric and physical 
consequences related to NPS consumption23, 17 (Simonato et al., 2013; Martinotti et al., 
2015a). Originally, the most common NPS were phenethylamines and tryptamines. In 
recent years cathinones, synthetic cannabinoids (Spice), phencyclidine and benzofurans 
have gained increasing popularity (EMCDDA, Annual Report 2015) 24. A number of NPS 
have been directly or indirectly associated with serious adverse effects and fatalities: 2-
DPMP and D2PM, two synthetic stimulants belonging to the class of piperidines, have 
shown both neuropsychiatric and cardiovascular toxicity, and have been involved in three 
deaths in August 2010 25(Corkery, Elliott, Schifano, et al. 2012). Misuse of gamma-
hydroxybutyrate (GHB) and gamma-butyrolactone (GBL) has been implicated in more than 
150 fatalities in the UK from 1995 to 2013 26(Corkery JM, Loi B, et al., 2015) and, more 
recently, stimulant mixtures and synthetic cannabinoids have emerged as potentially life-
threatening 27(Santacroce et al., 2015). Moreover, the use of novel synthetic opioids is 
another relevant issue, with an increasing number of deaths in the US and Canada due to 
overdose. 
NPS use is widespread among adolescents/young adults and frequent among psychiatric 
patients reporting psychotic symptoms at disease onset: Also, there is substantial evidence 
that NPS are a major risk factor for violence and aggression in patients with major mental 
disorders28,29,30, 31 [Soyka, 2000; Fazel et al. 2018; Shafi A et al. 2017; Martinotti G., 
Cinosi E, et al 2017]. 
 
Substance-Related Psychoses 
Substance use often co-occurs with schizophrenia and other psychiatric disorders. Rates of 
substance use disorder (SUD) among psychiatric patients are significantly higher than in the 
general population (up to 50%) (Jablensky et al. 2000) 32. High levels of comorbidity add to 
the diagnostic difficulties faced by clinicians and researchers in accurately differentiating 
substance-induced psychopathology from primary psychiatric disorders in the context of co-
occurring SUD. According to the DSM-5, between 7% and 25% of first-episode psychosis 
subjects have a Substance-induced Psychosis (SIP) (American Psychiatric Association, 
2013). Subjects with chronic and heavy substance use (cannabis, amphetamines, 
psychedelics, cocaine) are at highest risk. There is a growing recognition that substance use 
is associated with the emergence of psychosis, which develops during the use of the 
substance, and may or may not subside following withdrawal or abstinence. SIP subjects 
often call the police or ambulance and present in emergency rooms because they or 
family/friends feel a need for urgent intervention. Substance use, often heavy and long-term, 
suddenly transforms the subject’s perception and/or cognition into frightening experiences 
that are not recognized as due to acute intoxication and require an urgent response. Some 
subjects may have been experiencing substance-induced psychotic phenomena for months 
before the symptoms motivate help-seeking. Despite this, surprisingly little research has 
focused on differentiating SIP from primary psychotic disorders (PP) with substance use, 
especially with regards to determining whether these disorders have different trajectories 
and outcomes (Weibell, Hegelstad, and Johannessen 2016) 33. Little is known about 
potential factors associated specifically with SIP and the adequacy of current classification 
systems in appropriately distinguishing between primary and substance-induced disorders is 
questionable (Mathias, Lubman, and Hides 2008; Rounsaville 2007) 34,35. The phenomenon 
of substances causing transient psychotic states was first mentioned in studies from the 
1960s (Angrist and Gershon 1970) 36, with several experimental studies demonstrating drug 
effects mimicking the positive (e.g., hallucinations, delusions, paranoia and disorganized 
thinking) and negative (e.g., affective flattening, anhedonia, attentional and cognitive 
impairment) symptoms of schizophrenia34. Current major neurobiological theories of 
schizophrenia have their origin in the effects of substances: the effects of lysergic acid 
diethylamide (LSD) gave rise to the serotonergic model; amphetamines to the dopamine 
hypothesis; phencyclidine (PCP) and ketamine to the glutamatergic model and, more 
recently, the effects of cannabis have provoked interest in the role of endocannabinoids. 
Numerous substances are linked to the development of psychosis and diagnoses of SIP have 
been included in both the International Classification of Diseases 10 (ICD-10) (World 
Health Organization (WHO) 1992) and the Diagnostic and Statistical Manual of Mental 
Disorders 5 (DSM-5) (American Psychiatric Association. 2013) 37,38. The fourth edition of 
the DSM first introduced the term SIP in 1994. In the DSM-5, the diagnostic criteria for SIP 
essentially remain unchanged. SIP is defined as a condition in which psychotic symptoms 
(hallucinations and/or delusions) arise during or soon after substance 
intoxication/withdrawal and resolve within a set time period. Psychotic symptoms cannot 
occur exclusively during the course of a delirium. According to the DSM-5, symptoms 
should be more severe than those expected to occur with intoxication or withdrawal, and 
they should warrant the need for health care. There should be a lack of insight into 
hallucinations and delusions and symptoms should resolve within the somewhat loosely 
defined timeframe of “about a month” (American Psychiatric Association. 2013). ICD-10 
has a slightly different and more stringent time criterion in that it requires partial resolution 
within 1 month and full resolution of symptoms within 6 months. In clinical practice, 
distinguishing between SIP and PP with concurrent substance use remains a diagnostic 
difficulty 39(Schanzer et al. 2006). Misdiagnoses have major implications in terms of 
clinical management resulting in suboptimal follow-up and inappropriate treatment, with a 
potentially poorer prognosis (Mathias et al., 2008) 40. In the DSM, a diagnosis of SIP is 
based on the assumption that symptoms are transient and disappear after sustained 
abstinence. Literature suggests that diagnostic change over time is common: rate of change 
from SIP to PP ranges from 25% to 50% (Caton et al. 2007; Crebbin et al. 2009) 41,42. A 
recent meta-analysis reports that SIP is associated with a substantial risk for transition to 
schizophrenia, particularly following cannabis-induced psychosis (Murrie et al. 2019) 43. 
High transition rates are partly related to progression of the psychotic disorder (i.e., SIP 
develops into PP), and partly a result of the narrowed definition of SIP that may favor 
misdiagnosis (i.e., SIP diagnosed as Schizophreniform Disorder or  Psychosis NOS when 
criteria for schizophrenia are not fulfilled) (Mathias, Lubman, and Hides 2008) 40. Neither 
the ICD-10 nor the DSM-V allow for coding of “persistent states” of SIP, in spite of 
growing literature suggesting that in some chronic users psychotic symptoms can last 
substantially longer than the indicated timeframes (Weibell, Hegelstad, et al, 2017; Weibell, 
Johannessen et al 2019). 44,45 The diagnosis should then be changed from SIP to PP. But 
even then, the question of whether chronic substance use induces a long-lasting, clinically 
distinct psychotic syndrome or whether it precipitates a primary psychotic disorder (i.e., 
schizophrenia) remains unanswered. The problem of differential diagnosis has hampered 
research on the specific psychopathology and the prospective outcomes of individuals with 
psychoses following substance use (Wilson, Szigeti et al. 2017) 46. These psychotic 
disorders may be a separate diagnostic entity from PP that is stable over time and has 
distinctive psychopathological features.  
In the present contribution, we aim to outline a novel and separate clinical entity, Substance-
Related Exogenous Psychosis (SREP). As previously stated, the narrowed definition of SIP 
does not consider the issue of persistent psychoses that are clinically distinct from PP. 
Within this novel diagnostic category we refer to both transient and persistent forms of 
psychoses induced by substances (i.e., with onset following substance use). SREP can be 
considered a schizophrenia spectrum disorder but displays specific characteristics that 
clearly differentiate it from Schizophrenia/PP, in terms of clinical presentation, 
epidemiology, etiological models and treatment response.  
 
Substance Related Exogenous Psychosis:  etiopathology and psychopathological 
models 
Epidemiological data regarding prevalence and distribution of SREP has highlighted 
relevant differences compared to primary psychoses. Prevalence rates of schizophrenia are 
similar around the world (American Psychiatric Association. 2013) 38, whereas SREP 
typically emerges in the modern and developed world and has been mostly described in 
urban areas with high population density and rapid economic growth, where substance use 
represents a possible way to cope with ‘social acceleration’ and high levels of 
environmental stressors. 
Significant differences have also been hypothesized from a psychopathological perspective. 
Phenomenologically-oriented researchers propose that a disturbance of the basic self is a 
phenotypic trait marker of psychotic vulnerability (Sass and Parnas 2003) 47. This 
hypothesis is based on a combination of empirical research and philosophical 
considerations. The type of self-disturbance proposed as being a core abnormality in 
schizophrenia is a pre-reflective level of selfhood (ipseity). Self-disorders become 
progressively more articulated and thematized as psychotic symptoms develop, crystallizing 
in the form of delusions, hallucinations and passivity phenomena. When substance use 
becomes a relevant factor in the development of  a psychotic experience, this model needs 
to be integrated by a wider perspective. As previously discussed, a substantial number of 
substance users (especially if use is continuous and heavy) present persistent psychotic 
symptoms, opening questions regarding substance use and the development of a full, 
atypical chronic psychosis. In this context, the hexogen model of psychosis and its toxic 
subtype, defined lysergic psychoma, may be helpful in the understanding of substance-
induced phenomena. The term “lysergic psychoma” was first used by Cargnello and Callieri 
in 1963, though it has its roots in Hellpach’s definition and in the Karl Bonhoeffer’s 
hexogen model48. It describes a syndrome characterized by a clear egodystonic experience 
in which the subject perceives the presence of a “foreign body” in his mind. The thinking 
Ego can feel and observe it as an uncommon experience, out of control, enriched by 
hallucinations (mainly visual and kinesthetic), delusional perceptions and, in some cases, 
structured but confined delusional thoughts. The Ego is still aware and “in charge”, and 
usually tries to suppress the psychoma.  
This experience is usually transient and self-limiting, strictly connected to the 
pharmacodynamic effects exerted by the substance. However, repeated and heavy exposure 
as well as the long-lasting pharmacokinetic properties of some NPS open up a possible new 
scenario. When the thinking Ego has to face a recurring and intense abnormal experience 
(i.e., unusual thoughts or perceptions), its resilience weakens and its capacity to contain the 
experience fails. If the psychoma becomes stable, the capacity to offset it is progressively 
reduced and it invades the functioning part of the Ego. The lysergic psychoma is an 
exogenous clinical expression that almost all substance users experience, regardless of the 
substance type. Clearly, the pharmacodynamics of the drug taken is responsible for the 
specificity of the induced phenomena. The dopaminergic psychoma is most frequently 
reported as long-lasting and has the worst prognosis, as described for shaboo and 
methamphetamine users in south-eastern Asia. Methamphetamine-induced psychosis 49 is, 
in fact, a severe form of paranoid schizophrenia, in which the psychoma has become fully 




Substance Related Exogenous Psychosis: clinical and psychopathological 
characteristics 
 
In terms of clinical presentation, SREP exhibits specific features. Descriptive studies found 
specific clinical characteristics that distinguish psychoses associated with substance use 
from schizophrenia and that may drive differential diagnosis. Caton et al. identified key 
demographic, family and clinical differences between SIP and PP in 400 participants with at 
least 1 psychotic symptom, use of alcohol and/or other drugs in the previous 30 days and no 
psychiatric inpatient history in the previous 6 months. 50 SIP patients had more visual 
hallucinations, a higher prevalence of suicidal thoughts during the previous year, more 
violent behavior, family history of substance use and higher levels of insight. Other 
systematic studies aiming to characterize SIP as defined by DSM-5 and persistent, atypical 
psychotic disorders associated with substance use (i.e., SREP) are lacking and descriptions 
are mostly anecdotal. We briefly discuss possible distinctive clinical and 
psychopathological features associated with SREP, as reported in existing descriptive 
studies.  
The intersection between drug intoxication and psychosis is an altered state of 
consciousness, with a dramatic reduction in the field of consciousness (twilight state or 
crepuscular consciousness). The field of consciousness is restricted to a few, or even a 
single content. Depersonalization or derealization are typical and reversible experiences that 
characterize the twilight state. The latter is often also accompanied by illusions and 
hallucinosis and may represent a transitory state between the transient substance-induced 
psychotic experience and a full-blown, persistent psychosis. Psychosis emerging from 
crepuscular consciousness is marked by cognitive alterations, perceptual and thought 
disorders, affective symptoms. When normal consciousness is restored (i.e., the fiels of 
consciousness widens again) it sometimes opens up to new meaning in the context of a 
transformed, delusional reality experience. Both quantitative and qualitative alterations of 
consciousness should be routinely assessed in patients with a probable alcohol/substance 
use. These alterations are unusual in psychiatric disorders, with the exception of dissociative 
disorders, frequently described in literature as substance-induced symptoms 51 (Vik, 
Cellucci, Jarchow & Hedt, 2004), and may help guide early differential diagnosis.  
Modification of affectivity accompanied by depersonalization and derealization have been 
widely described 52,53 (G. Messas et al. 2018; Di Petta 2016). Several studies report 
affective symptoms (e.g., depressed mood, self-neglect and hostility) and suicidal 
ideation54,55,56 (Akiyama, Saito, and Shimoda 2011; Fraser et al. 2012; Hides et al. 2015). 
Affective symptoms are possibly a core clinical feature of SREP and are not recognized in 
current diagnostic criteria 57 (Voce et al. 2019).  
Delusions, mostly persecutory/paranoid, are usually secondary to abnormal perception 
resulting from a characteristic “sensorialization” of the world and of experience58,53 (G. 
Messas 2013; Di Petta 2016). Messas observed these features in a population of crack users 
in San Paolo (Brazil) and described several fundamental elements of these psychoses, partly 
related to cultural and social post-modern determinants: a) hyperstability, a form of 
existence based on the experience of the present, cut off from the past and future; b) 
freezing of the sense of time, with inability to wait and invest in the future; c) hyper-
materiality, where the sense of space and time are condensed in the present experience; d) 
non-evolving, crystallized delusions, that remain condensed inside the experience of present 
time. These psychopathological correlates emphasize the role of substances as mediators of 
social drifts. These delusional experiences are unstable, in a rapid-changing on-off state, and 
insight is fluctuating. 
Typically, intact insight has been reported as a common feature among patients with SREP 
59,60, 53 (Matsumoto et al. 2002; Martinotti et al. 2015; Di Petta 2016). DSM-5 criteria 
consider hallucinations/delusions as symptoms of SIP only when they occur in the absence 
of insight and suggest that a substance user with hallucinations/delusions and insight into 
these should be coded as having “perceptual disturbances”. However, SREP patients appear 
more likely to interpret symptoms as a result of substance use compared to PP patients.  
Hallucinations and other perception disorders are frequently reported in SREP. Visual and 
cenesthetic hallucinations are more common. This is probably related to the potent 
interaction exerted on the 5HT receptors by modern hallucinogens, like MDMA and other 
similar compounds. In SREP, perceptual alterations probably pave the way to thought 
disorders. Drastic substance-induced changes of the perception-movement cycle may 
influence judgment. Therefore, substance-induced delusions are not primary, but secondary 
to intense changes and distortions of perception. Substance-induced delusions are 
characterized by confirmation and interpretation, not by revelation, and by fantastic 
contents. In line with the lysergic psychoma model, SREP delusions are similar to 
paraphrenic delusions, with a feeling of unreality, while the ability to analyze the feeling is 
preserved60 (Martinotti et al., 2015b). 
Aggressiveness appears to be transnosographic, probably representing an intrinsic element 
correlated with substance use. SREP patients generally have high levels of impulsivity and 
often display violent behavior and severe psychomotor agitation (e.g., bizarre/disorganized 
behavior and motor hyperactivity) 50 (Caton et al. 2005). Polysubstance use has also 
demonstrated a strong correlation with aggression in emergency departments, together with 
higher risks of unprotected sex, car accidents, violence and victimization 61 (Goldstick, 
Stoddard, Carter, Zimmerman, et al 2016). Positive urine drug screen results for cannabis 
have been associated to a higher incidence of inpatient agitation among patients admitted to 
a psychiatric inpatient unit with a diagnosis of schizophrenia, schizoaffective disorder or 
bipolar disorder  62(Johnson, Wu, Winder, et al 2016). 
 
 
Substance Related Exogenous Psychosis: pharmacological models of clinical 
presentation 
SREP can be differentiated into specific syndromes, associated with the use of different 
compounds. Substances may precipitate the imbalance of a wide range of neurotransmitters, 
pathways and receptors: dopamine (DA, mostly associated with psychedelic 
phenethylamines/synthetic cathinones); CB-1R activation (synthetic cannabimimetics); 5-
HT2A receptor activation (tryptamine derivatives/hallucinogenic plants); antagonist 
activities at both NMDA and mGlu2/3 receptors (PCP-like derivatives); and k opioid 
receptor activation (Salvia divinorum).  
Substances mainly acting on dopaminergic pathways are primarily associated with paranoid 
thoughts and auditory hallucinations. Delusions of reference, persecution, grandeur and 
jealousy, as well as hypomanic states, are frequently reported. Aggressiveness and 
irritability are common, often with dysphoria, anxiety and panic episodes. With 
mephedrone, low mood, loss of appetite, difficulty sleeping, paranoid ideation, cognitive 
impairment, changes in perception, agitation, hallucinations, amnesia, confusion, violence 
and suicidal thoughts have been reported 63, 64,65,66,67(Homman et al. 2018; Sullivan S, 
Herzig D et al., 2013; Kehr et al., 2011; Capriola, 2013; Lovrecic & Lovrecic, 2017). Users 
also reported positive effects (e.g., euphoria, improved psychomotor speed, alertness, and 
talkativeness) 68,69,70 (Deruiter WK, Cheng et al., 2013; Dargan PI, Albert S, et al, 2010; 
Mdege et al., 2017) . Cathinone-induced acute intoxication may include symptoms of the 
serotonin syndrome, such as aggression and hyperthermia, psychotic symptoms, catatonia 
and hyperactive delirium 71,72,73,74,75,76,77,78(Warrick et al., 2013; Mugele et al., 2012; 
Hohmann et al., 2014; Denysenko et al., 2015; Otachbachi et al., 2010; Penders & Gestring, 
2011; Weaver et al., 2015; Turner J, Mitchell JL et al., 2015; Penders et al., 2012). Mood 
disturbances and paranoid ideation have been observed in chronic users of cathinones. 
Rasmon Kalayasiri’s study (2018)79  reports that up to 40% of individuals who use 
methamphetamine may experience psychotic symptoms or paranoia.  
Consistent with their pharmacological profile, those molecules that present with high 
serotonin: dopamine ratios may be considered analogous to entactogenic substances, such as 
MDMA. Conversely, high dopamine:serotonin ratios might predict a strong stimulant 
experience. Furthermore, high or low affinity to modulation of noradrenergic systems might 
be associated with varying sympathetic nervous system activation, whereas activation of 5- 
HT2A/1A receptors would more likely predict hallucinogenic effects80 (Baumeister et al., 
2015). 
Substances acting predominantly on serotonergic pathways are most commonly implicated 
in the development of visual hallucinations with vivid colors, frequently associated with 
intense positive or negative emotional experiences. Hallucinogens are also called 
‘psychedelics’ (e.g., LSD) and psilocybin, ‘psychotomimetics’ (a term emphasizing their 
effects mimic psychotic symptoms) and ‘entheogens’ (due to the mystical-type experiences 
these drugs may induce). Hallucinogens may induce hallucinations, illusions and ‘pseudo-
hallucinations’ (hallucinations recognized by the patient not to be the result of external 
stimuli), together with intense emotional responses and thoughts that may influence the 
human psyche 81 (Schifano 2016). In order of frequency, the other possible disordered 
perceptions are kinesthetic and tactile. The presence of auditory, olfactory and gustatory 
hallucinations is uncommon. Paranoid delusions, particularly with religious content, are 
possible, but full-blown systematic delusions are rare. A mood alteration towards 
hypomanic states may be reported, although suicidal thoughts and depression states may 
occur as well. The predominant clinical effects of tryptamines consist in visual 
hallucinations, alterations in sensory perception, distortion of body image, 
depersonalization, marked mood lability and anxiety/panic. 
Substances mainly acting on glutamatergic pathways usually determine dissociative 
reactions, such as derealization and somatopsychic depersonalization. Visual abnormal 
perception may be reported, mainly in the form of distortions and illusions. Bodily and 
kinesthetic hallucinations are frequent, as is the occurrence of near-death experiences. Less 
common are auditory, olfactory and gustatory hallucinations. Delusions with somatic 
themes are frequent: Ekbow, Capgras and Cotard syndromes have been reported, as well as 
episodes of demoniac possession and vexation. Psychotic negative symptoms are common. 
Mood is always flat, with affective blunting, anhedonia and a general sense of anesthesia 
and detachment from the surrounding environment is frequent. Irritability and 
aggressiveness may be noted. The ‘K-hole’ is an out-of-body/near-death experience, with 
the user becoming trapped in a state of detachment from physical presence. Residual 
symptoms, such as flashbacks and perceptual distortions, may follow. 
Cannabis intoxication is associated with anxiety and transient psychosis-like or 
psychotomimetic effects that include depersonalization, derealization, ideas of reference, 
grandiose and paranoid delusions, flight of ideas, disorganized thinking, and auditory and 
visual hallucinations. Such effects have been increasingly reported with high THC-
containing strains of cannabis and synthetic cannabinoids (“spice,” “K2,” and “kush”), 
generally CB1R and CB2R full agonists. 
Whilst low-dosage levels of synthetic cannabinoids produce similar psychoactive effects to 
cannabis/THC, with higher dosages auditory/visual hallucinations, anxiety and intense 
feelings of paranoia often occur 82,83(Bonaccorso et al, 2018; Winstock and Barratt, 2013a). 
Other psychiatric and neurological effects include: behavioral dyscontrol and agitation 
84(Brakoulias, 2012); mood swings 85(Celofiga et al., 2014); suicidal ideation, suicide 
attempts; panic attacks; thought disorganization; and hyperactive delirium 86(Schifano et al., 
2017). A florid/acute transient psychosis; relapse/worsening of a pre-existing psychosis and 
bipolar disorder 87,88(Oluwabusi et al., 2012; Ustundag et al., 2015); and persistent 
psychotic disorder/‘Spiceophrenia’ 89,81(Papanti, Schifano, Botteon et al., 2013; Schifano et 
al., 2016) have all been described. Intoxication/acute toxic effects of SCs appear to be more 
akin to those experienced with sympathomimetic/stimulant drug use90,91 (Wood and 
Dargan, 2012; Naviglio et al., 2015). It is interesting to note that some SCs exhibit 
pharmacologically relevant affinity for psychosis-associated receptors, including D2, 5-
HT2A, or NMDA. Skryabin et al 92(2019) highlighted four clinical variants of SC-induced 
psychoses:  1. Psychosis with predominant delirium symptoms; 2. Psychosis with 
predominant hallucinatory symptoms; 3. Psychosis with predominant affective-delusional 
symptoms; 4. Psychosis with predominant mental automatism. 
Substances acting on the opiate system do not usually determine clear psychotic syndromes. 
NSOs toxicity includes drowsiness, sedation, disorientation, slurred speech, confusion, 
dizziness, nausea, miosis, slowed breathing and respiratory depression93 (Suzuki and El-
Haddad, 2017). Conversely, NSOs psychotropic effects include: anxiolysis; euphoria; 
feeling of relaxation; mood lift, dysphoric and dissociating effects 94 (Solimini et al., 2018) 
(Table 2). Other compounds classified among NSOs are desomorphine (‘krokodil’), 
mitragynine and 7-Hydroxymitragynine (alkaloids found in “kratom”/Mitragyna speciose) 
95 (Megan A. Rech. Et al 2014) and salvinorin A, with its analogue herkinorin, which are 
the main Salvia divinorum components. Salvinorin A psychoactive effects include 
perceptual disturbances, psychosis, irritability and anxiety. 
A range of experiences may be associated with gabapentinoid high-dosage abuse, including 
euphoria, improved sociability, opiate-like sedation, entactogenic feelings/dissociation and 
psychedelic effects 81 (Schifano et al., 2016).  
These phenomena (serotonergic, dopaminergic and glutamatergic psychoma) cannot be 
considered as different syndromes, given the frequent overlap of symptoms among them. 
This is due to the fact that some NPS exert their effect on different pathways, and also 
because the possibility of polyabuse is the norm rather than the exception. However, the 
ability to differentiate and characterize clinical presentation may be useful to plan an 
appropriate therapeutic approach.  
 
Conclusion 
There is a clear need for a new diagnostic framework that provides reliable, unambiguous 
clinical criteria to differentiate between comorbid conditions (i.e., schizophrenia patients 
with SUD) and clinically distinct psychoses associated with substance use. Moreover, 
psychotic phenomena following substance use in patients with a primary diagnosis of mood 
(bipolar) disorder or borderline personality disorder need to be recognized and clearly 
distinguished from other forms of psychoses. Also, early differential diagnosis and staging 
between persistent psychoses associated with substance use (i.e., SREP) and transient 
psychotic states occurring during substance intoxication/withdrawal is necessary. In this 
paper we address these issues and make a first attempt to bridge this gap by discussing 
current literature on psychoses associated with substance use and proposing a new clinical 
and diagnostic entity, Substance-Related Exogenous Psychosis (SREP). SREP is conceived 
as a distinct psychotic disorder with its psychopathological specificities that develops 
following mostly chronic substance use and persists well beyond use. This distinction may 
have important implications for choice of treatment interventions (i.e., the contentious issue 
of long term antipsychotic medication in substance-related phenomena) (Dawson, et al 
2008). Potent and highly rewarding NPS are frequently associated with SREP and will 
likely challenge and shape substance-related psychopathology for years to come. SREP is 
highly represented in our post-modern liquid society, marked by instantaneity and rapid 
transformation, where substance use is often an adaptive trait. Elements of post-modernity 
(i.e., instability of self-identity) dominate contemporary social contexts and possibly operate 
as existential background conditions that contribute to the emergence of psychotic 
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